AzTrials
AzTrials

Laser TherapyPhase 3NCT07281690

Enhancing Skin Rejuvenation Using Laser and Exosomes

A Phase 3 study testing 1064-nm Nd:YAG Laser Treatment and Topical Umbilical Cord-Derived Exosomes (UC-MSC Exosomes) in people with Laser Therapy and Exosomes, run by Laser Beamer Skincare at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Enhancing Skin Rejuvenation A Single-Blind, Randomized Control Study on the Combined Efficacy of Aerolase 1064 nm YAG Laser and Exosomes Derived from Umbilical Cord Mesenchymal Stem Cells Read more about this study

Who is it for?
Ages 45 to 70 years, women onlyHealthy volunteers can take part
Conditions the study is for
Laser Therapy, Exosomes
What is being tested?
1064-nm Nd:YAG Laser Treatment and Topical Umbilical Cord-Derived Exosomes (UC-MSC Exosomes)
Type of treatment
Medical device
Could I receive a placebo?
No, everyone receives an active treatment
How many people
20 participants
Where
1 siteUnited States
Study dates
1 Mar 2025to 17 Jul 2025
Phase
Phase 3
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 45 to 70 years
  • Women only
  • Healthy volunteers accepted
  • Adult, Older adult

Who may be able to join

  • Females between the ages of 45-70

Who cannot join

  • Women who are pregnant

Trial locations and contacts

1 site in 1 country.

United States1 site
  • LaserBeamerSkincare

    Wichita, Kansas, 67212

Other trials in United States

About this study

Official title: Enhancing Skin Rejuvenation A Single-Blind, Randomized Control Study on the Combined Efficacy of Aerolase 1064 nm YAG Laser and Exosomes Derived From Umbilical Cord Mesenchymal Stem Cells

Enhancing Skin Rejuvenation A Single-Blind, Randomized Control Study on the Combined Efficacy of Aerolase 1064 nm YAG Laser and Exosomes Derived from Umbilical Cord Mesenchymal Stem Cells

Read the detailed description
  1. Brief Summary This study evaluates the combined efficacy of the Aerolase 1064-nm Nd:YAG laser and umbilical cord-derived mesenchymal stem cell (UC-MSC) exosomes for skin rejuvenation. The investigation uses a single-blind, randomized, split-face design to compare laser alone versus laser plus topical exosomes. Participants undergo facial analysis, laser treatment, and structured follow-up assessments to measure changes in skin redness, wrinkles, spots, tone, and overall skin quality.
  2. Detailed Description Detailed Description The study is conducted in Wichita, Kansas, a city of approximately 400,000 residents. Women constitute roughly 50% of the population, with an estimated one-third between ages 45-70. The percentage needed for this study represents less than 1% of the target demographic. Recruitment begins after IRB approval, with approximately 20 hours per week devoted to screening, enrolling, treating, and evaluating participants.

All study procedures occur at a single clinical site. The Principal Investigator (PI) is responsible for all recruitment, study activities, laser treatments, data entry, and follow-up coordination. The PI has over 30 years of nursing experience, including extensive clinical practice in women's health and mental health. Two additional nurse practitioners are available for consultation in case of medical concerns.

Participants are provided with study-related materials, including a consent form, PRO-X exosome information, a study protocol handout, and sunscreen. Eligible participants undergo baseline 3D HALO facial analysis and the initial Aerolase laser treatment. Participants draw a randomized ticket indicating "L" or "R," determining which facial side receives exosome application. The PI remains blinded to the allocation throughout the study.

Follow-up visits occur on Days 30, 45, and 60, with automated reminders sent via the clinic scheduling platform. Participants may contact the study site at any time with questions or concerns.

  • Number of Subjects Twenty female participants are recruited from the Wichita metropolitan area. A minimum of ten participants is considered acceptable for study viability. All study visits occur at a single site.
  • Recruitment Methods Recruitment uses flyers, social media posts, the clinic's website, Google business page, and professional networking meetings. Interested individuals contact the study site through phone, email, text message, or online scheduling. Eligibility screening includes verification of age and availability for the full study period.
  • Study Duration Total participation time ranges from 60-80 days. Follow-up windows allow for minor scheduling adjustments. Total enrollment is expected to take 3-4 weeks, with full study completion-including data analysis-estimated at 180 days.
  • Procedures Involved
  1. Standardized skin evaluation questionnaire on Days 1, 30, 45, and 60.
  2. HALO 3D facial imaging on Days 1, 30, 45, and 60.
  3. Aerolase 1064-nm Nd:YAG laser treatment to the full face at each visit.
  4. Randomized assignment of exosome application to either the left or right facial side.
  5. Twice-daily exosome application at home on the assigned side.
  6. Daily sunscreen use on the full face for the duration of the study. The study design is a single-blind, randomized, controlled, interventional trial evaluating changes in key skin parameters, including moisture, laxity, wrinkles, pigmentation, texture, tone, radiance, and pore size.

HALO Analyzer devices automatically calibrate before each session, ensuring consistency in measurement. Identical photographic conditions are maintained across all time points.

Laser treatments follow Aerolase manufacturer guidelines tailored to Fitzpatrick skin type. The PI is trained in all device operations, ensuring standardization across sessions.

  1. Data Management Objective data are collected through the HALO Analyzer and stored under de-identified subject numbers. Paired t-tests are used to compare pre- and post-treatment values for each facial side. The paired design accounts for within-subject variability.

Data verification includes cross-checking HALO outputs with participant self-assessments. Photographic documentation is reviewed immediately after capture to ensure clarity.

14.2 Confidentiality and Data Security All participant data-including photographs and self-assessments-are stored on a password-protected computer in a locked office. De-identified numeric codes replace participant names after enrollment. Only the PI and designated blinded nurse practitioner raters have access to study data.

Data will be securely retained for three years.

  • Protecting Privacy of Subjects Participants are assigned a unique study number upon enrollment. All study forms, HALO images, and assessments are stored under this number. Only the PI has access to identifying information required for scheduling or follow-up communication. Nurse practitioner raters evaluate photos labeled with de-identified numbers only.
  • Future Use of Data De-identified data will be maintained for three years and may be used for scientific publication or future research analyses as stated in the consent. No identifiable information will be released.
  • Ensuring Safety of Subjects Risks are minimal and may include transient redness or irritation from the laser or topical products.
  • Withdrawal of Subjects Participants may withdraw at any time for scheduling or personal reasons. Withdrawal reasons will be documented when possible. Data from participants who withdraw prior to completing the study will not be included in the final analysis.
Being tested
1064-nm Nd:YAG Laser Treatment, Topical Umbilical Cord-Derived Exosomes (UC-MSC Exosomes)

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • 1064-nm Nd:YAG Laser TreatmentDevice

    A non-ablative 1064-nm Nd:YAG laser (Aerolase Neo Elite) delivered to the entire face at each treatment visit.

  • Topical Umbilical Cord-Derived Exosomes (UC-MSC Exosomes)Biological

    Description:

    Topical application of a laboratory-processed umbilical cord lining mesenchymal stem-cell-derived exosome serum.

    Applied twice daily to the randomly assigned half of the face for 60 days following each laser session.

    Other Name: Exosome serum; UC-MSC exosome solution.

Study groups in NCT07281690
Study groupRoleWhat they receive
Experimental (Split-Faced Design)ExperimentalAll participants received a 1064-nm Nd:YAG laser treatment to the entire face. Exosomes (UC-MSC-derived topical serum) were applied only to the randomly assigned side of the face. The opposite side received laser only.
Receives: Device: 1064-nm Nd:YAG Laser Treatment; Biological: Topical Umbilical Cord-Derived Exosomes (UC-MSC Exosomes)

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Title: Mean Change in Nurse-Photographic Rating Scores Between Exosome-Treated and Control Sides

    Primary Outcome Measure 1

    Description:

    This outcome measures the difference between the exosome-treated and control sides using independent evaluations by three nurse practitioners. Ratings are scored on a 1-3 scale (1 = left side better, 2 = right side better, 3 = no difference).

    Time Frame: Day 60 Scoring Interpretation: Higher values indicate greater improvement on the exosome-treated side.

    Measured: 60 days

Secondary outcomes (1)
  1. Title: Mean Change in HALO Image Pro 3D Analyzer Scores (Redness, Wrinkles, Pigmentation, Tone)

    Primary Outcome Measure 2

    Description:

    This outcome measures changes in HALO imaging parameters (redness, wrinkles, pigmentation, and tone) between the exosome-treated and control sides.

    Time Frame: Day 30 and Day 60 Scoring Interpretation: Higher scores represent greater improvement.

    Measured: 60 days

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted15 Dec 2025
  2. Study start1 Mar 2025
  3. Primary completion17 Jul 2025
  4. Study completion17 Jul 2025

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Model description
Subjects receive lasering on their entire face and apply exosomes to a randomly assigned side of one side of their face. 3 laser sessions and 60 days of exosomes applied daily.
Masking
None (open label)
Enrolment
20 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07281690
Sponsor's protocol ID
25-08-089-2058
Status last verified
Oct 2025
First submitted
27 Oct 2025
Last updated
15 Dec 2025
Results posted
No
Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
Individual data sharing
Undecided: Individual participant data (IPD) from this study will not be shared. The dataset includes small-sample photographic images and FACE-Q responses that cannot be fully de-identified without compromising participant privacy. In addition, the study was not designed with external data sharing as a planned component.

Questions about this trial

What is this clinical trial studying?

A Phase 3 study testing 1064-nm Nd:YAG Laser Treatment and Topical Umbilical Cord-Derived Exosomes (UC-MSC Exosomes) in people with Laser Therapy and Exosomes, run by Laser Beamer Skincare at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 15 Dec 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Title: Mean Change in Nurse-Photographic Rating Scores Between Exosome-Treated and Control Sides (time frame: 60 days). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Dec 2025.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in